glp 1 new indications What's next for GLP-1 innovation: A primer on the race reshaping pharma and chronic disease care Updated guidance from the PCDS

The consistency of our test results lends robustness to our findings

Weight cycling, weight gain, and risk of hypertension in women

Expand ecosystem partnerships Partner with health platforms, clinicians and wellness influencers to validate claims

What the clinical evidence shows Several large, peer-reviewed studies have quantified the risk: The STEP 1 trial (NEJM, 2021): patients on high-dose semaglutide lost an average of 14.9% of their body weight over 68 weeks

Adequate hydration may also help minimize constipation, a common semaglutide side effect

The broader field of peptides for brain function is exploring similar neuroprotective mechanisms across multiple peptide families